Overview

A Study to Evaluate the Efficacy and Safety of Topical Administration of FMX101 in the Treatment of Moderate-to-Severe Acne Vulgaris

Status:
Completed

Trial end date:
2018-09-04

Target enrollment:

Participant gender:

Summary

A Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Efficacy and Safety of Topical Administration of FMX101 for 12 Weeks in the Treatment of Moderate-to-Severe Acne Vulgaris (Study FX2017-22)

Phase:

Phase 3

Details

Lead Sponsor:

Foamix Ltd.
Vyne Therapeutics Inc.

Treatments:

Minocycline